Bio Green Med Solution, Inc.

As of June 30, 2026, Bio Green Med Solution, Inc. carries a market capitalization of 6.03M, placing it among publicly traded companies globally. Its enterprise value stands at 2.24M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Bio Green Med Solution, Inc.'s next confirmed earnings release is scheduled for November 18, 2026.

As of June 30, 2026, Bio Green Med Solution, Inc. has 6.62M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 2.15, and the price-to-book ratio stands at 0.84.

These figures are as of June 30, 2026. The EV/Sales ratio of 1.20 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 2.24M versus a market cap of 6.03M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Bio Green Med Solution, Inc. maintains a current ratio of 8.63, meaning it holds 8.6x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Bio Green Med Solution, Inc. posted a negative return on equity (ROE) of -42.31, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -35.92, reflecting losses generated across the asset base. The company generates approximately 155,083.33 in revenue per employee across its workforce of 12.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Bio Green Med Solution, Inc. recorded 44,000.00 in income tax expense. The company reported a pretax loss of -2.16M and -2.20M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Bio Green Med Solution, Inc.'s stock has declined approximately 62.25% over the past 52 weeks. The 50-day moving average sits at 0.90, while the 200-day moving average is 0.98.

Over the twelve months ended June 30, 2026, Bio Green Med Solution, Inc. generated 1.86M in revenue and converted that into -2.20M in net income, yielding earnings per share of -0.50. EBITDA reached -2.73M, while operating income came in at -2.74M.

As of June 30, 2026, Bio Green Med Solution, Inc. holds 3.79M in cash and equivalents against - - in total debt, resulting in a net debt position of -3.79M. Total book value stands at 7.16M, with working capital of 5.28M providing operational flexibility.

Bio Green Med Solution, Inc. produced -1.10M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1,000.00 in capital expenditures, free cash flow totaled -1.10M - equivalent to -0.25 per share.

Over the twelve months ended June 30, 2026, Bio Green Med Solution, Inc. posted a gross margin of 19.34, reflecting its pricing power and cost economics. The operating margin of -147.13 and net profit margin of -118.27 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Bio Green Med Solution, Inc. paid dividends of 0.01 per share. The dividend payout ratio of 0.88 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -27.46: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -10.22, meaning Bio Green Med Solution, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Bio Green Med Solution, Inc.'s most recent stock split took place on July 7, 2025 with a 15:1 split ratio.

As of June 30, 2026, Bio Green Med Solution, Inc. has an Altman Z-Score of -96.30, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.